BillionToOne, Inc. Class A Common Stock
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is BLLN moving today?
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
BLLN overview
Related filings and maps
Congress activity in BLLN
No receipt-qualified Congressional disclosure is present for BLLN in the cached public ledger.
BLLN contract awards, year to date.
Public federal awards linked to this ticker.
BLLN lobbying filings, year to date.
Registered lobbying filings matched to BillionToOne, Inc. Class A Common Stock.